Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i3b.1367Keywords:
Tacrolimus, CYP3A5, Paediatric, Liver Transplant, Living Donor, Pharmacogenetics, Precision MedicineAbstract
Background. In the paediatric liver transplant programme in Johannesburg, South Africa (SA), tacrolimus is the calcineurin inhibitor of choice, comprising an essential component of the immunosuppression regimen. It is characterised by a narrow therapeutic index and wide interpatient variability, necessitating therapeutic drug monitoring of whole-blood concentrations. Pharmacogenetic research, although not representative of SA population groups, suggests that single-nucleotide polymorphisms within the cytochrome P450 3A5 (CYP3A5) gene contribute to the variability in tacrolimus dosing requirements. The rs776746 polymorphism, CYP3A5*3, results in a splice defect and a non-functional enzyme. Clinically, to reach the same tacrolimus concentration-to-dose ratio (CDR), expressors (CYP3A5*1/*1 and *1/*3) require a higher tacrolimus dose than non-expressors (*3/*3).
Objectives. To compare the pharmacokinetics of tacrolimus in paediatric liver transplant recipients with their donors’ CYP3A5 genotypes, considering both donor and recipient characteristics.
Methods. Blood samples from 46 living liver donors were collected, their genomic DNA was extracted, and their CYP3A5 genotype was established (polymerase chain reaction and restriction fragment length polymorphism analysis, validated by Sanger sequencing). The relationship of donor and recipient characteristics with the mean tacrolimus CDR was analysed using a general linear model. Non- confounding significant variables were included in a multiple regression model.
Results. The study showed that all expressor donors genotyped as CYP3A5*1/*1 were of black African self-reported race and ethnicity. During the first 15 days post-transplant, we found that children who received grafts from donor CYP3A5 expressors (CYP3A5*1/*1 and *1/*3) had significantly lower mean tacrolimus CDRs compared with those who received grafts from donor CYP3A5 non-expressors (*3/*3); the recipients of CYP3A5 expressor grafts therefore require higher doses of oral tacrolimus to achieve the same therapeutic target range. In addition, graft-to-recipient weight ratio and the CYP3A5 donor genotypes were independent factors that significantly (p<0.05) affected mean tacrolimus CDRs in recipients.
Conclusion. In this study, we showed that all CYP3A5*1 homozygote donors were of black African self-reported race and ethnicity, and tacrolimus CDRs in paediatric living-donor liver transplant recipients were significantly affected by donor graft size and donor CYP3A5 genotypes. Information from this study may inform the development of an Afrocentric tacrolimus precision-medicine algorithm to optimise recipient safety and graft outcomes.
References
Botha JF, Ströbele B, Loveland J, et al. Living donor liver transplantation in South Africa: The donor
experience. S Afr J Surg 2019;57(3):11-16. https://doi.org/10.17159/2078-5151/2019/v57n3a2998
Bruckmann EK, Beretta M, Demopolous D, et al. Minding the gap – providing quality transplant care
for South African children with acute liver failure. Pediatr Transplant 2020;24(8):e13827. https://doi.
org/10.1111/petr.13827
Fabian J, Loveland J, Maher H, et al. Wits Transplant Annual Data Report 2018: Adult and paediatric liver
transplantation. Wits J Clin Med 2019;1(3):109-122. https://doi.org/10.18772/26180197.2019.v1n3a2
Spada M, Riva S, Maggiore G, Cintorino D, Gridelli B. Pediatric liver transplantation. World J
Gastroenterol 2009;15(6):648-674. https://doi.org/10.3748/wjg.15.648
Pinon M, de Nicolò A, Pizzol A, et al. Early impact of donor CYP3A5 genotype and graft-torecipient
weight ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. Sci Rep
;11(1):443. https://doi.org/10.1038/s41598-020-79574-7
Muller WK, Dandara C, Manning K, et al. CYP3A5 polymorphisms and their effects on tacrolimus
exposure in an ethnically diverse South African renal transplant population. S Afr Med J 2020;110(2):159-
https://doi.org/10.7196/SAMJ.2020.v110i2.13969
Botha J, Masimirembwa C, Ramsey M, Scholefield J, Fabian J. A precision medicine approach to
tacrolimus pharmacokinetics after pediatric LDLT in an ethnically diverse population. Pediatr
Transplant 2022;26(14269):81-82. https://doi.org/10.1111/petr.14269
Shi B, Liu Y, Liu D, et al. Genotype-guided model significantly improves accuracy of tacrolimus
initial dosing after liver transplantation. eClinicalMedicine 2023;55:101752. https://doi.org/10.1016/j.
eclinm.2022.101752
He J, Yu Y, Yin C, et al. Clinically significant drug-drug interaction between tacrolimus and fluconazole
in stable renal transplant recipient and literature review. J Clin Pharm Ther 2020;45(2):264-269.
https://doi.org/10.1111/jcpt.13075
Rodriguez-Antona C, Savieo JL, Lauschke VM, et al. PharmVar GeneFocus: CYP3A5. Clin Pharmacol
Ther 2022;112(6):1159-1171. https://doi.org/10.1002/cpt.2563
Wan P, Hou Y, Qiu B, et al. GRWR correlates with the metabolism of tacrolimus after pediatric living donor
liver transplantation according to donor CYP3A5 polymorphism. Biomed Res Int 2022;2022:7647754.
https://doi.org/10.1155/2022/7647754
Miloh T, Barton A, Wheeler J, et al. Immunosuppression in pediatric liver transplant recipients: Unique
aspects. Liver Transpl 2017;23(2):244-256. https://doi.org/10.1002/lt.24677
Calvo PL, Serpe L, Brunati A, et al. Donor CYP3A5 genotype influences tacrolimus disposition on the
first day after paediatric liver transplantation. Br J Clin Pharmacol 2017;83(6):1252-1262. https://doi.
org/10.1111/bcp.13219
Xue F, Han L, Chen Y, et al. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious
complications in Chinese pediatric liver transplant patients. Pediatr Transplant 2014;18(2):166-176.
https://doi.org/10.1111/petr.12216
Jacobo-Cabral CO, García-Roca P, Romero-Tejeda EM, et al. Population pharmacokinetic analysis of
tacrolimus in Mexican paediatric renal transplant patients: Role of CYP3A5 genotype and formulation.
Br J Clin Pharmacol 2015;80(4):630-641. https://doi.org/10.1111/bcp.12649
Zheng HX, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is
related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003;3(4):477-483. https://doi.
org/10.1034/j.1600-6143.2003.00077.x
Zheng HX, Zeevi A, Schuetz E, et al. Tacrolimus dosing in adult lung transplant patients is related
to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 2004;44:135-140. https://doi.
org/10.1177/0091270003262108
Chen YK, Han LZ, Xue F, et al. Personalised tacrolimus dose requirement by CYP3A5 but not ABCB1
or ACE genotyping in both recipient and donor after pediatric liver transplantation. PLoS ONE
;9(10):e109464. https://doi.org/10.1371/journal.pone.0109464
PharmGKB. Gene-specific information tables for CYP3A5. 2022. https://www.pharmgkb.org/page/
cyp3a5RefMaterials (accessed 25 November 2022).
Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterisation of the
genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27(4):383-391. https://doi.
org/10.1038/86882
Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism.
Pharmacogenetics 2001;11(9):773-779. https://doi.org/10.1097/00008571-200112000-00005
Da Rocha JEB, Othman H, Botha G, et al. The extent and impact of variation in ADME genes in
sub-Saharan African populations. Front Pharmacol 2021;12:634016. https://doi.org/10.3389/
fphar.2021.634016
Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and chronic rejection after
liver transplantation: What a clinician needs to know. J Clin Exp Hepatol 2017;7(4):358-366. https://
doi.org/10.1016/j.jceh.2017.10.003
Flanagin A, Frey T, Christiansen SL; AMA Manual of Style Committee. Updated guidance on the
reporting of race and ethnicity in medical and science journals. JAMA 2021;326(7):621-627. https://
doi.org/10.1001/jama.2021.13304
Statistics South Africa. Mid-year population estimates 2022. Statistical release P0302. Pretoria: Stats
SA, 2022. https://www.statssa.gov.za/publications/P0302/P03022022.pdf (accessed 24 May 2023).
Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human
nucleated cells. Nucleic Acids Res 1988;16(3):1215. https://doi.org/10.1093/nar/16.3.1215
Ali SA, Soo C, Agongo G, et al. Genomic and environmental risk factors for cardiometabolic diseases
in Africa: Methods used for Phase 1 of the AWI-Gen population cross-sectional study. Glob Health
Action 2018;11(sup2):1507133. https://doi.org/10.1080/16549716.2018.1507133
Kalt DA. Tacrolimus: A review of laboratory detection methods and indications for use. Lab Med
;48(4):e62-e65. https://doi.org/10.1093/LABMED/LMX056
Uesugi M, Masuda S, Katsura T, Oike F, Takada Y. Effect of intestinal CYP3A5 on postoperative
tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics
;16(2):119-127. https://doi.org/10.1097/01.fpc.0000184953.31324.e4
Maldonado AQ, Asempa T, Hudson S, Rebellato LM. Prevalence of CYP3A5 genomic variances and
their impact on tacrolimus dosing requirements among kidney transplant recipients in eastern North
Carolina. Pharmacotherapy 2017;37(9):1081-1088. https://doi.org/10.1002/phar.1970
Csikány N, Kiss Á, Déri M, et al. Clinical significance of personalised tacrolimus dosing by adjusting to
donor CYP3A-status in liver transplant recipients. Br J Clin Pharmacol 2021;87(4):1790-800. https://
doi.org/10.1111/bcp.14566
Helal M, Obada M, Elrazek WA, Safan M, El-Hakim TA, El-Said H. Effect of ABCB1 (3435C>T) and
CYP3A5 (6986A>G) genes polymorphism on tacrolimus concentrations and dosage requirements
in liver transplant patients. Egypt J Med Hum Genet 2017;18(3):261-268. https://doi.org/10.1016/j.
ejmhg.2016.10.005
Ebid AHIM, Ismail DA, Lotfy NM, Mahmoud MA, ELSharkawy M. Influence of CYP3A4*22 and
CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant
patients. J Clin Pharm Ther 2022;47(12):2255-2263. https://doi.org/10.1111/jcpt.13804
Goto M, Masuda S, Kiuchi T, et al. CYP3A5*1-carrying graft liver reduces the concentration/
oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics
;14(7):471-478. https://doi.org/10.1097/01.fpc.0000114747.08559.49
Downloads
Published
Issue
Section
License
Copyright (c) 2024 C Wheeler, C Masimirembwa, B Mthembu, J Botha, J Scholefield, J Fabian
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
